A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Cholangiocarcinoma
Interventions
DRUG

Gemcitabine, Capecitabine and Bevacizumab

Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

43210

Ohio State University, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER